Armando Anido

Zynerba Pharmaceuticals R&D Expenses For Q1 Reach $7.1M, Here Are The Details
Zynerba Pharmaceuticals R&D Expenses For FY22 Reach $21.1M, What About Net Loss?
What's The Role Of The Endocannabinoid System In Fragile X Syndrome? How Can Cannabidiol Treatment Help? New Paper
Zynerba Pharmaceuticals R&D Expenses For FY22 Reach $21.1M, What About Net Loss?
What's The Role Of The Endocannabinoid System In Fragile X Syndrome? How Can Cannabidiol Treatment Help? New Paper
CBD-Based Zygel Helps With Anxiety-Related & Behavioral Symptoms In 22q11.2 Deletion Syndrome, Phase 2 Trial Reveals
Zynerba Pharmaceuticals R&D Expanses For Q2 Reach 5.4M, Here Are The Details

Armando Anido Recent News

Zynerba Pharmaceuticals Completes Enrollment For CBD Transdermal Trial For 22q Deletion Syndrome
Manufacturer of transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, Zynerba Pharmaceuticals, Inc.
Cannabis Movers & Shakers: Cresco, Agricor & Botanacor, C3 Industries, Akanda, CULTA, OWP, Zynerba
Cresco Labs Taps Megan Kulick To Serve As VP Of Investor Relations
Zynerba Pharmaceuticals Names New CLO & Corporate Secretary
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has appointed Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, as chief legal officer and corporate secretary.
Zynerba's Shares Jump on CBD Zygel Trial Plans, Company Reports Cash Until 2024
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) disclosed Wednesday its first-quarter net loss of $8.0 million or a loss of 20 cents per share, compared to $12.34 million in the same period of 2020 or a loss of 53 cents per share. First Quarter Highlights
Zynerba CEO Talks Election, Balance Sheet And Huge Osteoarthritis Market Potential